Inspira Technologies

Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. Inspira was incorporated in 2018 with a clear mission: to develop a cost-effective, less-invasive respiratory support system as an alternative to mechanical ventilation used today to save the lives of patients with acute respiratory failure. The company’s first of its kind early extracorporeal respiratory support system, The ART500 device, designed to elevate and stabilize patient oxygen saturation levels while the patient is awake. The ART500 device is intended as an artificial assisting lung. It withdraws blood through a dual lumen cannula inserted into the jugular vein, enriches it with a high concentration of oxygen, removes CO2, and returns the enriched blood to rebalance patients’ saturation levels and take the load off the lungs. The product is currently in a developmental stage and has not yet been tested or used in humans and has not been cleared/approved by the U.S. Food and Drug Administration (FDA).